Union Bancaire Privee UBP SA Makes New $45,000 Investment in ARK Genomic Revolution ETF (BATS:ARKG)

Union Bancaire Privee UBP SA acquired a new stake in ARK Genomic Revolution ETF (BATS:ARKG) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,910 shares of the company’s stock, valued at approximately $45,000.

Several other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in ARK Genomic Revolution ETF by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock worth $75,655,000 after purchasing an additional 698,701 shares during the period. Barclays PLC boosted its stake in shares of ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after acquiring an additional 204,283 shares during the period. PFM Health Sciences LP bought a new position in shares of ARK Genomic Revolution ETF during the 3rd quarter worth approximately $2,226,000. Quadrature Capital Ltd acquired a new position in shares of ARK Genomic Revolution ETF during the 3rd quarter worth approximately $1,970,000. Finally, Elmwood Wealth Management Inc. raised its stake in ARK Genomic Revolution ETF by 7.7% in the 4th quarter. Elmwood Wealth Management Inc. now owns 62,191 shares of the company’s stock valued at $1,464,000 after acquiring an additional 4,425 shares during the period.

ARK Genomic Revolution ETF Price Performance

ARKG stock opened at $25.21 on Wednesday. The stock’s 50 day moving average is $25.88 and its two-hundred day moving average is $25.41.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.